RNC-NICU Practice Test 2026 – The Comprehensive All-in-One Study Resource for Registered Nurse Certification Success!

Choosing an antifungal agent for neonatal Candida infections hinges on finding a drug that is effective against Candida, safe for the fragile neonatal patient, and practical for dosing in the NICU.

Fluconazole fits these needs well. It can be given IV or orally, which makes it versatile in the NICU where patients may be unable to take oral meds initially. It has good systemic penetration, including the central nervous system, so it can treat invasive candidiasis that may involve the bloodstream or meninges. In neonates, fluconazole is generally well tolerated and has a simpler dosing and monitoring profile compared with amphotericin B, which carries a higher risk of nephrotoxicity and infusion reactions. Because it covers most Candida species commonly seen in newborns, it’s widely used for both mucosal and invasive candidiasis and can be employed as step-down therapy after initial stabilization.

Nystatin is typically reserved for mucosal candidiasis and isn’t effective for systemic infection. Amphotericin B is used for severe systemic disease but has notable toxicity. Ketoconazole is less favored in neonates due to toxicity and limited CNS penetration.

So, fluconazole is commonly chosen because it combines effective Candida coverage with a favorable safety and practicality profile for neonatal care.